Piper Keenan, DePledge Lisa, Karsy Michael, Cobbs Charles
Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, United States.
Sidney Kimmel Medical College, Philadelphia, PA, United States.
Front Oncol. 2021 Feb 24;11:615704. doi: 10.3389/fonc.2021.615704. eCollection 2021.
Glioblastoma is the most common and lethal primary brain malignancy. Despite major investments in research into glioblastoma biology and drug development, treatment remains limited and survival has not substantially improved beyond 1-2 years. Cancer stem cells (CSC) or glioma stem cells (GSC) refer to a population of tumor originating cells capable of self-renewal and differentiation. While controversial and challenging to study, evidence suggests that GCSs may result in glioblastoma tumor recurrence and resistance to treatment. Multiple treatment strategies have been suggested at targeting GCSs, including immunotherapy, posttranscriptional regulation, modulation of the tumor microenvironment, and epigenetic modulation. In this review, we discuss recent advances in glioblastoma treatment specifically focused on targeting of GCSs as well as their potential integration into current clinical pathways and trials.
胶质母细胞瘤是最常见且致命的原发性脑恶性肿瘤。尽管在胶质母细胞瘤生物学研究和药物开发方面投入巨大，但治疗手段仍然有限，患者生存期在1至2年之后并无显著改善。癌症干细胞（CSC）或胶质瘤干细胞（GSC）是指一群具有自我更新和分化能力的肿瘤起源细胞。虽然对其研究存在争议且颇具挑战，但有证据表明，胶质瘤干细胞可能导致胶质母细胞瘤肿瘤复发和治疗耐药。针对胶质瘤干细胞已提出多种治疗策略，包括免疫疗法、转录后调控、肿瘤微环境调节以及表观遗传调节。在本综述中，我们将讨论胶质母细胞瘤治疗的最新进展，特别关注针对胶质瘤干细胞的治疗方法，以及它们融入当前临床路径和试验的潜力。
